Nevada Medicaid and Nevada Check Up News (First Quarter 2024 Provider Newsletter) [Read]

Attention Behavioral Health Providers: Monthly Behavioral Health Training Assistance (BHTA) Webinar Scheduled [See Web Announcement 2009]

Attention All Providers: Requirements on When to Use the National Provider Identifier (NPI) of an Ordering, Prescribing or Referring (OPR) Provider on Claims [Announcement 850]

If you are a Medicaid provider whose revalidation application has not been processed by your termination due date, you will be ineligible to provide services to any Nevada Medicaid or Nevada Check Up recipients, including both Fee-for-Service and Managed Care Organization (MCO) enrolled recipients. See Web Announcement 1265

Enrollment Termination Frequently Asked Questions (FAQs) [Review]

Notifications

URGENT Electronic Visit Verification (EVV) Claims Message: EVV claims submitted through Sandata between noon Pacific Time on Monday, April 8, 2024, and 6 a.m. Pacific Time on Tuesday, April 9, 2024, were received for processing by Gainwell on Wednesday, April 17, 2024. As a result, payment of the impacted claims will be unfortunately delayed by one week and paid April 26, 2024, instead of April 19, 2024. No action is required on your part. Nevada Medicaid is working to avoid this happening again in the future and apologizes for the inconvenience this payment delay causes during this period of EVV claim submission challenges because of the Change Healthcare cyber security event.

URGENT Electronic Visit Verification (EVV) Claims Message: EVV claims submitted through Sandata after noon Pacific Time last Thursday, April 4, 2024, were received for processing by Gainwell on Monday, April 8, 2024. As a result, payment of the impacted claims will be unfortunately delayed by one week and paid April 19, 2024, instead of April 12, 2024. No action is required on your part. Nevada Medicaid is working with Sandata to avoid this happening again in the future and apologizes for the inconvenience this payment delay causes during this period of EVV claim submission challenges because of the Change Healthcare cyber security event.

Electronic Visit Verification (EVV) Claim Update: Providers using Sandata for claims submission are advised to allow 24 hours after claim submission for claim details to be visible in the Medicaid Management Information System (MMIS). Please be advised that claims must be submitted before noon Pacific Time on Fridays to be included in the following weeks’ remittance advice.

URGENT NOTIFICATION: Physician Administered Drug (PAD) claims may be experiencing a host eligibility error. The impacted claims will be reprocessed automatically. No action is needed by providers.

Unwinding COVID-19 Information

Known System Issues-Click HERE

Feedback Requested Regarding the Gabby™ Interactive Voice Response (IVR) System Survey

Attention Providers Using the Authorization Criteria Function: Results that return prior authorization (PA) requirements are accurate. For results that return “There are no records found based on the search criteria,” there may be a PA requirement if limits have been exceeded. To verify PA requirements, please refer to the Medicaid Services Manual (MSM) Chapter for your service type at dhcfp.nv.gov and the Billing Guide for your provider type at www.medicaid.nv.gov.

Scheduled Site Maintenance

During the scheduled site maintenance window the Provider Web Portal will be unavailable. The table below shows the regularly scheduled maintenance window. All times will be in the Pacific time zone.

Monday - Friday
12:00AM - 12:30AM

Monday
8:00PM - 12:00AM

Month Title
April 2022 For Review at April 28, 2022 Meeting: Anxiolytics, Sedatives and Hypnotics
April 2022 For Review at April 28, 2022 Meeting: Movement Disorder Agents
April 2022 For Review at April 28, 2022 Meeting: Ophthalmic Agents, Intraocular Pressure (IOP)-Modifying
April 2022 For Review at April 28, 2022 Meeting: Respiratory and Allergy Biologics
October 2021 For Review at October 26, 2021 Meeting: Alzheimer’s Disease Agents
October 2021 For Review at October 26, 2021 Meeting: Angiotensin II Receptor Blockers (ARBs)
October 2021 For Review at October 26, 2021 Meeting: Antiemetics
October 2021 For Review at October 26, 2021 Meeting: Calcitonin Gene Related Peptide (CGRP) Inhibitors
October 2021 For Review at October 26, 2021 Meeting: Growth Hormone
October 2021 For Review at October 26, 2021 Meeting: Immunomodulators
July 2021 For Review at July 22, 2021 Meeting: Anti-Migraine Agents, Miscellaneous
July 2021 For Review at July 22, 2021 Meeting: Duchenne Muscular Dystrophy (DMD) Agents
April 2021 For Review at April 22, 2021 Meeting: Anticonvulsants
April 2021 For Review at April 22, 2021 Meeting: Calcitonin Gene Related Peptide (CGRP) Inhibitors
April 2021 For Review at April 22, 2021 Meeting: Hepatitis C Direct-Acting Antivirals
April 2021 For Review at April 22, 2021 Meeting: Hereditary Angioedema Agents
April 2021 For Review at April 22, 2021 Meeting: Multiple Sclerosis Agents
April 2021 For Review at April 22, 2021 Meeting: Narcolepsy Agents
April 2021 For Review at April 22, 2021 Meeting: Platelet Aggregation Inhibitors
January 2021 For Review at January 28, 2021 Meeting: Anticonvulsants
January 2021 For Review at January 28, 2021 Meeting: Duchenne Muscular Dystrophy (DMD) Agents
January 2021 For Review at January 28, 2021 Meeting: Neuropathic Pain and Fibromyalgia Agents
January 2021 For Review at January 28, 2021 Meeting: Spinal Muscular Atrophy (SMA) Agents
October 2020 For Review at October 22, 2020 Meeting: Bone Density Regulators
October 2020 For Review at October 22, 2020 Meeting: GnRH Modulators
October 2020 For Review at October 22, 2020 Meeting: Multiple Sclerosis Agents
October 2020 For Review at October 22, 2020 Meeting: Topical Analgesics/Antipruritics
July 2020 For Review at July 23, 2020 Meeting: Anticonvulsants
July 2020 For Review at July 23, 2020 Meeting: Antidepressants, Other
July 2020 For Review at July 23, 2020 Meeting: Antidepressants, Selective Serotonin Reuptake Inhibitors (SSRIs)
July 2020 For Review at July 23, 2020 Meeting: Anxiolytics, Sedatives and Hypnotics
July 2020 For Review at July 23, 2020 Meeting: Atypical Antipsychotics
July 2020 For Review at July 23, 2020 Meeting: Bone Density Regulators
July 2020 For Review at July 23, 2020 Meeting: Growth Hormones
July 2020 For Review at July 23, 2020 Meeting: Neuropathic Pain and Fibromyalgia Agents
July 2020 For Review at July 23, 2020 Meeting: Opioid Use Disorder Agents
July 2020 For Review at July 23, 2020 Meeting: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
April 2020 For Review at April 30, 2020 Meeting: Calcitonin Gene Related Peptide (CGRP) Inhibitors
April 2020 For Review at April 30, 2020 Meeting: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Dornase Alfa
April 2020 For Review at April 30, 2020 Meeting: Narcolepsy Agents
April 2020 For Review at April 30, 2020 Meeting: Oral Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
April 2020 For Review at April 30, 2020 Meeting: Proton Pump Inhibitors
April 2020 For Review at April 30, 2020 Meeting: Sickle Cell Anemia Agents
April 2020 For Review at April 30, 2020 Meeting: Smoking Cessation Agents
January 2020 For Review at January 23, 2020 Meeting: Antiasthmatic – Monoclonal Antibodies
January 2020 For Review at January 23, 2020 Meeting: Anticonvulsants
January 2020 For Review at January 23, 2020 Meeting: Irritable Bowel Syndrome and Constipation Agents
January 2020 For Review at January 23, 2020 Meeting: Multiple Sclerosis Agents
January 2020 For Review at January 23, 2020 Meeting: Narcolepsy Agents
October 2019 For Review at October 17, 2019 Meeting: Anti-inflammatory Agents – Misc., Topical
October 2019 For Review at October 17, 2019 Meeting: Enzyme Preparations and Wound Healing Products
October 2019 For Review at October 17, 2019 Meeting: Erythropoiesis Stimulating Agents
October 2019 For Review at October 17, 2019 Meeting: Narcolepsy Agents
October 2019 For Review at October 17, 2019 Meeting: Neuropathic Pain and Fibromyalgia Agents
October 2019 For Review at October 17, 2019 Meeting: Phosphodiesterase-4 Inhibitor for COPD
October 2019 For Review at October 17, 2019 Meeting: Respiratory Anticholinergics
October 2019 For Review at October 17, 2019 Meeting: Scabicides and Pediculicides
October 2019 For Review at October 17, 2019 Meeting: Zolgensma®
July 2019 For Review at July 25, 2019 Meeting: Anti-Migraine Agents (Triptans)
July 2019 For Review at July 25, 2019 Meeting: Growth Hormone
July 2019 For Review at July 25, 2019 Meeting: Irritable Bowel Syndrome and Constipation Agents
July 2019 For Review at July 25, 2019 Meeting: Spravato® (Esketamine)
April 2019 For Review at April 25, 2019 Meeting: Androgens
April 2019 For Review at April 25, 2019 Meeting: Attention-Deficit/Hyperactivity Disorder (ADHD) Agents
April 2019 For Review at April 25, 2019 Meeting: Fentanyl Immediate Release Products
April 2019 For Review at April 25, 2019 Meeting: Opioid Use Disorder Agents
April 2019 For Review at April 25, 2019 Meeting: Opioids, Long Acting
January 2019 For Review at January 24, 2019 Meeting: Angiotensin II Receptor Blockers (ARBs)
January 2019 For Review at January 24, 2019 Meeting: Anticonvulsants
January 2019 For Review at January 24, 2019 Meeting: Antivirals, Influenza
January 2019 For Review at January 24, 2019 Meeting: Inhaled Beta-Agonists
January 2019 For Review at January 24, 2019 Meeting: Oncology
January 2019 For Review at January 24, 2019 Meeting: Pulmonary Arterial Hypertension Agents